These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 17723126

  • 1. Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients.
    Fernandez-Cadenas I, Alvarez-Sabin J, Ribo M, Rubiera M, Mendioroz M, Molina CA, Rosell A, Montaner J.
    J Thromb Haemost; 2007 Sep; 5(9):1862-8. PubMed ID: 17723126
    [Abstract] [Full Text] [Related]

  • 2. [Relationship between plasma levels of thrombin activatable fibrinolysis inhibitor, plasminogen activator inhibitor-1 and tissue-type plasminogen activator and deep venous thrombosis in patients with systemic lupus erythematosus].
    Liu YF, Hou N, Shi YJ, Li CX, Gao YJ, Liu LN.
    Zhonghua Yi Xue Za Zhi; 2023 Jun 06; 103(21):1638-1642. PubMed ID: 37248064
    [Abstract] [Full Text] [Related]

  • 3. Association of TAFI gene polymorphisms with severity of coronary stenosis in stable coronary artery disease.
    Rattanawan C, Komanasin N, Settasatian N, Settasatian C, Kukongviriyapan U, Intharapetch P, Senthong V.
    Thromb Res; 2018 Nov 06; 171():171-176. PubMed ID: 30321704
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor and Plasminogen Activator Inhibitor-1 Reduces Ischemic Brain Damage in Mice.
    Denorme F, Wyseure T, Peeters M, Vandeputte N, Gils A, Deckmyn H, Vanhoorelbeke K, Declerck PJ, De Meyer SF.
    Stroke; 2016 Sep 06; 47(9):2419-22. PubMed ID: 27470988
    [Abstract] [Full Text] [Related]

  • 5. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
    Zorio E, Castelló R, Falcó C, España F, Osa A, Almenar L, Aznar J, Estellés A.
    Br J Haematol; 2003 Sep 06; 122(6):958-65. PubMed ID: 12956767
    [Abstract] [Full Text] [Related]

  • 6. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N, Guldiken S, Demir M, Tugrul A.
    Clin Appl Thromb Hemost; 2010 Oct 06; 16(5):568-73. PubMed ID: 19959491
    [Abstract] [Full Text] [Related]

  • 7. Assessment of plasminogen activator inhibitor-1(PAI1) and thrombin activitable fibrinolysis inhibitor (TAFI) in Egyptian children with hemophilia A.
    Soliman M, Osman N, Hefnawy S, El Hawy MA.
    Pediatr Hematol Oncol; 2022 May 06; 39(4):318-328. PubMed ID: 34668834
    [Abstract] [Full Text] [Related]

  • 8. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
    Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O.
    Eur J Endocrinol; 2009 May 06; 160(5):863-8. PubMed ID: 19233920
    [Abstract] [Full Text] [Related]

  • 9. Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator.
    Ribo M, Montaner J, Molina CA, Arenillas JF, Santamarina E, Alvarez-Sabín J.
    Thromb Haemost; 2004 Jun 06; 91(6):1146-51. PubMed ID: 15175801
    [Abstract] [Full Text] [Related]

  • 10. The hyperfibrinolytic state of mice with combined thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 gene deficiency is critically dependent on TAFI deficiency.
    Vercauteren E, Peeters M, Hoylaerts MF, Lijnen HR, Meijers JC, Declerck PJ, Gils A.
    J Thromb Haemost; 2012 Dec 06; 10(12):2555-62. PubMed ID: 23083123
    [Abstract] [Full Text] [Related]

  • 11. Fibrinolysis inhibitors in plaque stability: a morphological association of PAI-1 and TAFI in advanced carotid plaque.
    Jönsson Rylander AC, Lindgren A, Deinum J, Bergström GM, Böttcher G, Kalies I, Wåhlander K.
    J Thromb Haemost; 2017 Apr 06; 15(4):758-769. PubMed ID: 28135035
    [Abstract] [Full Text] [Related]

  • 12. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model.
    Nagashima M, Werner M, Wang M, Zhao L, Light DR, Pagila R, Morser J, Verhallen P.
    Thromb Res; 2000 May 15; 98(4):333-42. PubMed ID: 10822080
    [Abstract] [Full Text] [Related]

  • 13. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke.
    Leebeek FW, Goor MP, Guimaraes AH, Brouwers GJ, Maat MP, Dippel DW, Rijken DC.
    J Thromb Haemost; 2005 Oct 15; 3(10):2211-8. PubMed ID: 16092924
    [Abstract] [Full Text] [Related]

  • 14. Central nervous system bleeding in pediatric patients with factor XIII deficiency: a study on 23 new cases.
    Naderi M, Alizadeh S, Kazemi A, Tabibian S, Zaker F, Bamedi T, Kashani Khatib Z, Dorgalaleh A.
    Hematology; 2015 Mar 15; 20(2):112-8. PubMed ID: 25001244
    [Abstract] [Full Text] [Related]

  • 15. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
    Erem C, Nuhoglu I, Yilmaz M, Kocak M, Demirel A, Ucuncu O, Onder Ersoz H.
    J Endocrinol Invest; 2009 Feb 15; 32(2):169-74. PubMed ID: 19411818
    [Abstract] [Full Text] [Related]

  • 16. Active PAI-1 as marker for venous thromboembolism: case-control study using a comprehensive panel of PAI-1 and TAFI assays.
    Bollen L, Peetermans M, Peeters M, Van Steen K, Hoylaerts MF, Declerck PJ, Verhamme P, Gils A.
    Thromb Res; 2014 Nov 15; 134(5):1097-102. PubMed ID: 25193405
    [Abstract] [Full Text] [Related]

  • 17. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
    Chudý P, Kotuličová D, Staško J, Kubisz P.
    Blood Coagul Fibrinolysis; 2011 Sep 15; 22(6):493-8. PubMed ID: 21519232
    [Abstract] [Full Text] [Related]

  • 18. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.
    Akinci B, Comlekci A, Yener S, Demir T, Ozcan MA, Bayraktar F, Yesil S.
    Endocr J; 2007 Aug 15; 54(4):593-9. PubMed ID: 17690487
    [Abstract] [Full Text] [Related]

  • 19. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.
    Meltzer ME, Lisman T, de Groot PG, Meijers JC, le Cessie S, Doggen CJ, Rosendaal FR.
    Blood; 2010 Jul 08; 116(1):113-21. PubMed ID: 20385790
    [Abstract] [Full Text] [Related]

  • 20. Changes in Activated Thrombin-Activatable Fibrinolysis Inhibitor Levels Following Thrombolytic Therapy in Ischemic Stroke Patients Correlate with Clinical Outcome.
    Alessi MC, Gaudin C, Grosjean P, Martin V, Timsit S, Mahagne MH, Larrue V, Sibon I, Zuber M, Brouns R, Montaner J, Castellanos M, Donazzolo Y, Cho TH, Suissa L, Mechtouff L, Derex L, Suchon P, Mezzapesa A, Nighoghossian N.
    Cerebrovasc Dis; 2016 Jul 08; 42(5-6):404-414. PubMed ID: 27387478
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.